Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma: altered CD4/CD8 ratio in bone marrow.

V Redoglia1, M Boccadoro, S Battaglio

  • 1Dipartimento di Medicina ed Oncologia Sperimentale, Ospedale Maggiore S. Giovanni Battista, Torino, Italy.

Haematologica
|March 1, 1990
PubMed
Summary

Multiple myeloma (MM) patients show altered T-lymphocyte subsets, particularly a profound reduction in CD4+ cells within bone marrow. This T-cell imbalance is more pronounced in bone marrow than peripheral blood.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cutaneous involvement in multiple myeloma. A rare entity.

Clinical case reports·2025
Same author

Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

BCL-2 expression in primary cutaneous follicle center lymphoma is associated with a higher risk of cutaneous relapses: A study of 126 cases.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Multiple myeloma (MM) is a hematological malignancy characterized by abnormal plasma cells.
  • T-lymphocyte subsets play a crucial role in immune regulation and are often dysregulated in cancer.

Purpose of the Study:

  • To investigate the expression and distribution of T-lymphocyte antigens (CD3, CD4, CD8) in the peripheral blood and bone marrow of MM patients.
  • To analyze the coexpression of CD11b and HLA-DR within CD4+ and CD8+ T-cell subpopulations in MM.

Main Methods:

  • Flow cytometry was used to simultaneously evaluate CD3, CD4, and CD8 antigen expression on lymphocytes from peripheral blood and bone marrow of 22 MM patients.
  • Coexpression of CD11b and HLA-DR was analyzed in CD4+ and CD8+ T-cell subpopulations in 4 MM patients.

Related Experiment Videos

Main Results:

  • Peripheral blood showed normal CD3+ and CD8+ cell percentages, with slightly reduced CD4+ cells and an altered CD4/CD8 ratio in 7 patients.
  • Bone marrow exhibited a profound reduction in CD4+ cells, leading to an altered CD4/CD8 ratio in all MM patients.
  • An expansion of CD11b+ and HLA-DR+ lymphocytes was observed within CD4+ and CD8+ bone marrow T-cell subpopulations.

Conclusions:

  • A significant T-lymphocyte subset imbalance is evident in the bone marrow of MM patients, more so than in peripheral blood.
  • This imbalance is characterized by a profound decrease in CD4+ T-cells and an expansion of CD11b+ and HLA-DR+ T-cells within bone marrow.
  • The findings suggest a distinct immune microenvironment in the bone marrow of MM patients, potentially impacting disease progression and immune surveillance.